SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility

Expansion leverages proprietary chromatography expertise to overcome purification bottlenecks and secure domestic API manufacturing capacity.

We’ve just expanded our U.S. peptide development and manufacturing footprint, adding new SPPS + purification capacity at kilo scale specifically to help programs like yours avoid the bottlenecks we’re seeing across the market. What’s unique is that this isn’t a future promise; it builds on our existing U.S. infrastructure and our global manufacturing network across Europe and Asia.

The goal is to give innovators optionality and security, a single partner from early development through commercial readiness, with flexibility across regions based on strategy, timeline, or regulatory path.